Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Inflammatory Response01:28

Inflammatory Response

8.1K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
8.1K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.3K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The clinical profile of systemic sclerosis without a 'scleroderma pattern' at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of Rheumatology.

Journal of translational autoimmunity·2026
Same author

Could belimumab be a new weapon in autoimmune complicated CVID?

Frontiers in immunology·2026
Same author

Clinical and serological features of triple autoantibody-negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology.

RMD open·2026
Same author

Artificial Intelligence and Vitamin D Deficiency: Opportunities and Challenges for Clinical Translation in Chronic Diseases.

Frontiers in bioscience (Landmark edition)·2026
Same author

Clinical presentation and hospitalisation risk of RSV in primary care among children younger than 5 years in Italy in four seasons between 2019 and 2023: a multicentre prospective cohort study.

The Lancet regional health. Europe·2026
Same author

Changing Prevalence of Immunocompromising Conditions in Patients Hospitalized with Severe Acute Respiratory Infection in Europe: Insights from the COVIDRIVE Study.

Journal of epidemiology and global health·2026
Same journal

Conditional Immortalization of Human Cardiac Fibroblasts for Pro-Fibrotic and Anti-Fibrotic Drug Screening.

Frontiers in bioscience (Landmark edition)·2026
Same journal

NF-κB Involvement in Glaucoma-Associated Neuroinflammation: Focus on Glial Cells.

Frontiers in bioscience (Landmark edition)·2026
Same journal

Revealing the Molecular Network of Pattern-Triggered Immunity (PTI) Signal Transduction.

Frontiers in bioscience (Landmark edition)·2026
Same journal

Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.

Frontiers in bioscience (Landmark edition)·2026
Same journal

β-Ecdysterone Attenuates Ang II-Induced Senescence in Human Aortic Smooth Muscle Cells via Autophagy Activation and ROS Suppression Through AKT/mTOR Pathway Inhibition.

Frontiers in bioscience (Landmark edition)·2026
Same journal

Exploration of the Role of M2 Macrophages in Hepatocellular Carcinoma: Insights into Disulfidptosis and Cellular Interactions.

Frontiers in bioscience (Landmark edition)·2026
See all related articles

Related Experiment Video

Updated: Sep 17, 2025

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
06:29

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 1, 2011

26.5K

Interleukin-31: A Pro-inflammatory Oriented Cytokine.

Giuseppe Murdaca1,2, Francesca Paladin3, Andrea Orsi4,5

  • 1Department of Internal Medicine, University of Genova, Viale Benedetto XV, 16132 Genova, Italy.

Frontiers in Bioscience (Landmark Edition)
|July 4, 2025
PubMed
Summary
This summary is machine-generated.

Type 2 immunity, involving T helper 2 (Th2) cells and cytokines like IL-31, drives inflammatory skin diseases and cancer-associated pruritus. Targeting IL-31 and IL-33 offers new therapeutic avenues for itch relief.

Keywords:
IL-31IL-31 receptorsIL-33IL-33/IL-31 axiscancer

More Related Videos

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
10:30

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Published on: January 25, 2017

9.0K
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
09:04

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

21.0K

Related Experiment Videos

Last Updated: Sep 17, 2025

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
06:29

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 1, 2011

26.5K
Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
10:30

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Published on: January 25, 2017

9.0K
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
09:04

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

21.0K

Area of Science:

  • Immunology
  • Dermatology
  • Oncology

Background:

  • Type 2 immunity, mediated by T helper 2 (Th2) lymphocytes and cytokines (IL-4, IL-13, IL-31), is crucial in immune-mediated skin conditions like atopic dermatitis and psoriasis.
  • These immune pathways amplify inflammation, signaling cascades, and pruritus in dermatological disorders.
  • Interleukin-33 (IL-33) and Interleukin-31 (IL-31) are increasingly recognized for their linked roles in disease severity and pruritus.

Purpose of the Study:

  • To explore the role of IL-31 and IL-33 as key mediators in immune-mediated skin diseases and cancer-associated pruritus.
  • To investigate the potential of targeting these non-histaminergic cytokines as novel therapeutic strategies.
  • To review recent advancements in monoclonal anti-IL-31 therapies for improving patient quality of life.

Main Methods:

  • Review of existing literature on Type 2 immunity, Th2 lymphocytes, and associated cytokines.
  • Analysis of the role of IL-31 and IL-33 in the pathogenesis of atopic dermatitis, psoriasis, and cancer-related pruritus.
  • Discussion of emerging therapeutic approaches, including monoclonal antibodies targeting IL-31.

Main Results:

  • IL-31 and IL-33 are intrinsically linked, potentially amplifying inflammatory skin conditions and pruritus.
  • Elevated IL-31 levels can foster a tumor-promoting microenvironment and contribute to cancer-associated pruritus.
  • Non-histaminergic mediators like IL-31 and IL-33 present viable therapeutic targets.

Conclusions:

  • IL-31 and IL-33 play significant roles in the pathophysiology of pruritic immune-mediated skin diseases and cancer.
  • Targeting IL-31 and IL-33 offers a promising strategy for managing pruritus and enhancing patient quality of life.
  • Monoclonal anti-IL-31 therapies represent a significant innovation in treating these conditions.